TUCSON, Ariz. — HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that it has entered into a long-term agreement with Thermo Fisher Scientific under which HTG will have the right to develop a number of in-vitro diagnostic (IVD) tests for use with Thermo Fisher’s next-generation sequencing Ion PGM Dx System.

“We believe the combination of HTG EdgeSeq chemistry and automation platform with the Ion Torrent next-generation sequencing (NGS) platform is a great solution for clinical sequencing workflows in molecular diagnostic laboratories,” stated TJ Johnson, HTG’s CEO. “We believe this agreement will provide us important options for our planned diagnostic menu.”

About HTG Molecular Diagnostics:

Headquartered in Tucson, Arizona, HTG’s mission is to empower precision medicine at the local level. In 2013 the company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG’s proprietary nuclease protection chemistry. HTG’s product offerings have since expanded to include its HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing. Additional information is available atwww.htgmolecular.com.